ImmunoGen Announces Webcast of Presentation at the Jefferies Global Healthcare Conference
May 24 2017 - 8:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that Mark Enyedy, president and chief executive
officer, will present at the upcoming Jefferies 2017 Global
Healthcare Conference in New York, NY. The presentation is
scheduled for 3:30 pm ET on June 8, 2017.
A webcast of the presentation will be accessible live through
the "Investors" section of the Company's website,
www.immunogen.com; a replay will be available at the same location
for approximately 90 days.
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that
develops targeted cancer therapeutics using its proprietary ADC
technology. ImmunoGen's lead product candidate, mirvetuximab
soravtansine, is in a Phase 3 trial for FRα-positive
platinum-resistant ovarian cancer, and is in Phase 1b/2
testing in combination regimens for earlier-stage disease.
ImmunoGen's ADC technology is used in Roche's marketed product,
Kadcyla®, in three other clinical-stage ImmunoGen product
candidates, and in programs in development by partners Amgen,
Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More
information about the Company can be found at
www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including mirvetuximab soravtansine,
including risks related to preclinical and clinical studies, their
timings and results. A review of these risks can be found in
ImmunoGen's Annual Report on Form 10-K for the fiscal year ended
December 31, 2016 and other reports filed with the Securities and
Exchange Commission.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170524005152/en/
For InvestorsThrust IRMonique Allaire,
617-895-9511monique@thrustir.comorFor MediaFTI Consulting,
Inc.Robert Stanislaro,
212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024